HEALEY ALS, a platform trial testing multiple potential treatments for amyotrophic lateral sclerosis, is amending its master ...

Neurosense is finalizing the protocol of a Phase 3 study of PrimeC for ALS, and plans to submit the protocol for FDA approval ...

Columnist Kristin Neva must take on more caregiver duties as her husband's ALS progresses, which means she must shift her ...

The Centers for Medicare and Medicaid Services is directing all Medicare Advantage plans to cover Qalsody for treating ...

Worrying about symptom progression a year after her diagnosis, columnist Dagmar Munn decided to develop her own resilience ...

Dazucorilant failed to slow disease progression in ALS patients in the DAZALS Phase 2 clinical trial, but may have extended ...

The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.

Columnist Juliet Taylor's late husband, Jeff, always made Christmas special. To honor his memory, she carries on their ...

The delay in diagnosing ALS means treatment and supportive care is received later, which can have a significant impact on ...

Growing up in rural areas, having younger parents, and having less education may all be environmental risk factors for ALS, ...

MN-166 (ibudilast) appears to benefit ALS patients over up to one year of use, an interim Phase 2b/3 trial analysis suggests.